Publicaciones en las que colabora con José Pablo Miramontes González (14)

2025

  1. Corrigendum to “Evaluation of the effect of metformin as a radiosensitiser in solid tumours: A systematic review” [Clin. Translat. Radiat. Oncol. 52 (2025) 100930](S2405630825000205)(10.1016/j.ctro.2025.100930)

    Clinical and Translational Radiation Oncology

  2. Neoadjuvant chemoimmunotherapy or chemoradiotherapy in stage III non-small cell lung cancer: crossing the Rubicon?

    Chinese Clinical Oncology, Vol. 14, Núm. 5

2023

  1. Biomarkers for immunotherapy in non-small cell lung cancer: a current and future reality

    Precision Cancer Medicine

  2. Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data

    Cancers, Vol. 15, Núm. 17

  3. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis

    Chinese Clinical Oncology, Vol. 12, Núm. 6

  4. Reply to «Considerations to the manuscript cancer and elderly: Two incompatible concepts for intensive care?»

    Revista Espanola de Geriatria y Gerontologia

  5. The relationship between PARP inhibitors with the relapse and leukemisation of lymphomas: a case report

    AME CASE REPORTS

2022

  1. Cancer and elderly: Two incompatible concepts for intensive care?

    Revista Espanola de Geriatria y Gerontologia

  2. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy

    Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88

  3. Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Dopamine receptors and the kidney: An overview of health-and pharmacological-targeted implications

    Biomolecules, Vol. 11, Núm. 2, pp. 1-16

  2. Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors

    Life, Vol. 11, Núm. 12

  3. Resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: A new therapeutic targeting of haematological malignancies

    Journal of Clinical Medicine, Vol. 10, Núm. 9

  4. The influence of diet and probiotics on the response of solid tumours to immunotherapy: Present and future perspectives

    Applied Sciences (Switzerland), Vol. 11, Núm. 18